Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation.
COVID-19
Convalescent plasma
SARS-CoV-2
antibody escape
evasion
immune suppression
mutation
neutralising antibodies
resistance
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
29 Dec 2020
29 Dec 2020
Historique:
pubmed:
6
1
2021
medline:
6
1
2021
entrez:
5
1
2021
Statut:
epublish
Résumé
SARS-CoV-2 Spike protein is critical for virus infection via engagement of ACE2, and amino acid variation in Spike is increasingly appreciated. Given both vaccines and therapeutics are designed around Wuhan-1 Spike, this raises the theoretical possibility of virus escape, particularly in immunocompromised individuals where prolonged viral replication occurs. Here we report chronic SARS-CoV-2 with reduced sensitivity to neutralising antibodies in an immune suppressed individual treated with convalescent plasma, generating whole genome ultradeep sequences by both short and long read technologies over 23 time points spanning 101 days. Although little change was observed in the overall viral population structure following two courses of remdesivir over the first 57 days, N501Y in Spike was transiently detected at day 55 and V157L in RdRp emerged. However, following convalescent plasma we observed large, dynamic virus population shifts, with the emergence of a dominant viral strain bearing D796H in S2 and
Identifiants
pubmed: 33398302
doi: 10.1101/2020.12.05.20241927
pmc: PMC7781345
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : Wellcome Trust
ID : 206618/Z/17/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701652
Pays : United Kingdom
Organisme : NIGMS NIH HHS
ID : R01 GM083127
Pays : United States
Commentaires et corrections
Type : UpdateIn